Full-Time
Associate Director – Pharmacometrics Lead
Updated on 9/3/2026
Takeda
10,001+ employees
Global biopharmaceutical firm; R&D-driven NMEs
No salary listed
Bengaluru, Karnataka, India
Hybrid
Hybrid work arrangement; on-site in Bengaluru, India per policy.
Master's, PharmD, PhD
 Biology & Biotech (1) |
|---|
Get referred to Takeda
See people who can refer or advise you
- Provides scientific and strategic pharmacometric leadership for multiple projects on Global Program Teams and associated scientific and operational sub-teams with limited supervision.
- Independently drives and leads the formulating and delivery of the pharmacometrics component of the QP Plan.
- Key contributor and driver of pharmacometrics strategies, including Model-Informed Drug Development (MIDD) practices and advanced modeling and simulation approaches (e.g., QSP, MBMA, CTS) to inform internal decisions and external regulatory interactions.
- Represents Pharmacometrics, where required in global or regional regulatory agency meetings and be responsible for the technical component of the clinical pharmacology summary documents for regulatory submissions.
- Oversees and/or independently performs PK, PD, and pharmacometric analyses including the interpretation of PK/PD data in close partnership with DSI and external partners.
- Maintains a high standard for good clinical practice, compliance, and ethics.
- Mentors junior staff to promote scientific excellence and individual achievement.
- Participates as a member of Business Development due diligence, when requested.
- Contributes to infrastructure initiatives and/ or cross-functional best practice initiatives.
- Has scientific influence outside PMx and Takeda through presentations and publications and active contribution to scientific societies and cross-industry consortiums related to pharmacometrics such as working groups or sessions at ACCP, ASCPT, ACOP, PAGE, ISQP, IQ, and DIA.
- Pharm D. or PhD with 5+ years of working experience in a quantitative field with working experience in pharmacometrics, mechanistic modelling, statistics or chemical bio-engineering.
- MS with 8+ years' working experience in a quantitative field working experience in pharmacometrics and/or mechanistic modelling.
- Established skills in pharmacometrics and its application in early & late stage drug development programs.
- Able to oversee the technical aspects of out-sourced pharmacometrics work in collaboration with the QCP lead.
- Expert in use of some of the relevant software e.g. R, NonMem, STAN, SAS, Phoenix
- Solid mathematical and/or statistical background.
- Able to communicate results at both a technical and strategic level to non-experts.
- Comprehensive understanding of global regulatory expectations, stages of drug development and opportunities of the application of pharmacometrics within the drug development paradigm.
- Expert knowledge of regulatory guidance for industry applicable to pharmacometrics.
- Advanced knowledge and/or hands-on applications in integration of PK, PD, efficacy, and safety data from multiple sources for dose selection and decision-making.
- Independently works by delivering, and prioritizing PMx activities across projects with minimal supervision.
- Effectively drives and influences project teams towards objectives while enabling and making decisions.
- Focuses on priorities and delivers on commitments.
- Strong communication skills and ability to translate effectively across functional lines.
- Possess collaborative mindset, inspire teamwork, and is effective at building alliance across functions.
- Assess benefit/risk of options.
- Develop understanding of business beyond Pharmacometrics.
Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.
Company Size
10,001+
Company Stage
IPO
Headquarters
Tokyo, Japan
Founded
1781
Get referred to Takeda
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 2026 FDA approval of MIMRYLO opened a new U.S. polycythemia vera franchise.
- ORZEYFUL won U.S., Japan, and China approvals in August 2026, accelerating commercialization.
- Takeda maintained FY2026 guidance after Q1 2026, with 22.6% growth from new launches.
What critics are saying
- The May 18, 2026 Amitiza verdict imposed $884.9 million damages, tripling on judgment.
- Takeda's March 2026 restructuring cuts 4,500 jobs, signaling margin pressure and execution disruption.
- If ORZEYFUL, MIMRYLO, and zasocitinib underperform, Takeda's mature-brands decline crushes growth.
What makes Takeda unique
- Takeda’s 2026 launches target first-in-class mechanisms: MIMRYLO, ORZEYFUL, and zasocitinib.
- Takeda built rare Japan-to-global R&D depth, with oveporexton approved in China, U.S., Japan.
- Takeda paired discovery teams with Boltz in 2026, embedding AI across research.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Wellness Program
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%The FDA approved Takeda Pharmaceutical's MIMRYLO (rusfertide) for polycythemia vera, a blood cancer causing red blood cell overproduction. The first-in-class drug functions as a hepcidin mimetic, regulating iron distribution to control hematocrit levels and prevent life-threatening complications like strokes and pulmonary embolisms. Approval was based on the Phase 3 VERIFY study involving 293 patients. Those receiving MIMRYLO alongside standard care achieved superior hematocrit control, reduced phlebotomy needs, and improved fatigue compared to placebo. Takeda commercialises MIMRYLO under a 2024 agreement with Protagonist Therapeutics, which discovered the drug. The approval triggers $275 million in payments to Protagonist—a $200 million opt-out fee plus $75 million milestone. Protagonist remains eligible for up to $875 million in additional milestones and tiered royalties of 14% to 29% on worldwide net sales.
Takeda has received US FDA approval for MIMRYLO (rusfertide), a first-in-class treatment for erythrocytosis in adults with polycythemia vera (PV), a blood cancer. The drug is a hepcidin mimetic that regulates iron distribution and red blood cell overproduction to control hematocrit levels. The approval was supported by the Phase 3 VERIFY study involving 293 PV patients. Results showed MIMRYLO plus standard care demonstrated higher response rates than placebo, including better hematocrit control, reduced phlebotomy needs, and improved fatigue scores. PV affects approximately 90,000 people in the US. An estimated 78% of patients experience uncontrolled hematocrit with current standard care. The most common adverse events were injection site reactions and anaemia. MIMRYLO is administered once weekly via subcutaneous injection. Takeda is working with regulators outside the US for potential global availability.
Takeda announced Japan's Ministry of Health, Labour and Welfare has approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first to address the underlying orexin deficiency causing the disease, rather than just managing individual symptoms. Narcolepsy type 1 is a chronic neurological condition characterised by excessive daytime sleepiness, cataplexy, disrupted sleep, and other symptoms that significantly impact patients' daily lives. Diagnostic delays average more than 10 years. The approval follows global Phase 3 trials showing statistically significant improvements across the full range of symptoms. Common side effects included insomnia, urinary urgency and frequency, and excessive saliva. ORZEYFUL is also approved in China and the United States. Takeda developed the first-in-class orexin receptor 2 agonist in its Japanese laboratories and plans to launch the treatment quickly.
The US Food and Drug Administration has approved Takeda's ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first orexin receptor 2 agonist approved to address the underlying cause of the disease rather than individual symptoms. Narcolepsy type 1 is a chronic neurological disease affecting approximately 120,000 people in the US. It is driven by orexin deficiency and causes excessive daytime sleepiness, cataplexy, cognitive symptoms and disrupted sleep. Clinical trials showed adults taking ORZEYFUL experienced significant improvements across the full range of symptoms compared to placebo. Takeda is preparing for the US launch, which will proceed following completion of the Drug Enforcement Administration scheduling process. The company describes the approval as potentially redefining how narcolepsy type 1 is managed.
Seattle-based biotech startup Accipiter Biosciences has raised an additional $10.5 million, less than a year after emerging from stealth with $12.7 million. The funding, from existing investors including Flying Fish Partners and Takeda, will accelerate the company's drug development programmes. The startup uses AI tools developed at the University of Washington's Institute for Protein Design to engineer proteins that can bind multiple cellular targets simultaneously. The company has expanded to 22 employees, including researchers who worked under Nobel laureate David Baker. Accipiter Bio has partnerships with Pfizer and Gilead Sciences-owned Kite Pharma, with potential milestone payments exceeding $330 million. The additional funding will enable the company to advance three or four drug candidates into clinical trials, focusing on immunology and oncology.